The device will enable people with diabetes to:
- Eliminate painful finger pricks: The rt-CGM device will continuously monitor glucose levels in real-time and sending values wirelessly to a compatible smart device via the system mobile app or receiver, providing a complete picture of glucose levels and trends.
- Have exceptional accuracy: The user-friendly app and receiver display trend arrows to show the speed and direction that glucose levels are heading, helping make in-the-moment treatment decisions easier.
- Be offered a personalised experience: A range of personalised alerts warn of potentially dangerous high or low glucose events so action can be taken, with a delayed first alert feature to avoid alarm fatigue.
- Access to Dexcom Clarity: The data management software package provides remote data sharing with healthcare professionals, as well as trends and patterns at all times.
Shreya Mashru displays the new rt-CGM device
Karen Baxter, Vice President, UK and Ireland, Benelux, France and Spain at Dexcom: “The addition of Dexcom ONE to the NHS England, Wales, Scotland and Northern Ireland drug tariff is enormous progress towards improving choice of diabetes tech, providing an alternative to burdensome finger pricks and scanning. We are incredibly proud of the diabetes community and are working hard to make it easier for them to access the best technology possible to manage their diabetes. As a next step, we will be working closely with healthcare professionals to ensure the diabetes community can benefit as quickly as possible from reimbursement and wider availability of Dexcom CGM.”
Dexcom ONE is part of a range of CGM systems offered by Dexcom for people with diabetes in the UK that also includes the Dexcom G6 and the upcoming Dexcom G7. With the new portfolio of products, Dexcom meets the entire criteria set out by NICE.